BMY Bristol-Myers Squibb Earnings and EPS analysis

  1. Stocks
  2. Healthcare
  3. NYSE: BMY
  4. Earnings
?
Relative Growth: Rel. Growth: 74
Relative Strength: Rel. Strength: 77
Relative Valuation: Rel. Valuation: 86
Relative Profitability: Rel. Profitability: 96

EPS in 2026 (TTM): $4.55

Last Report Period Date: Jun 30, 2026

According to the most recent financial data from June 2026, the current EPS (TTM) is $4.55. Bristol-Myers Squibb's EPS for 2025 came in at $3.47, marking an increase from -$4.41 in 2024. For the quarterly period ending on Jun 30, 2026, BMY's EPS was $1.62.

BMY earnings history

Historical annual and quarterly earnings per share (EPS) data for Bristol-Myers Squibb
EPS (TTM)
$4.55
EPS Growth YoY (Quarterly)
153.1%
EPS (Quarterly)
$1.62
EPS Growth (Quarterly)
23.7%

Bristol-Myers Squibb had an annual EPS of $3.47, marking an increase of 178.7% from -$4.41 in 2024. The quarterly EPS for the period ending Jun 30, 2026, was $1.62, marking a 153.1% increase from the same quarter last year. BMY's TTM EPS stands at $4.55 as of June 2026. Bristol-Myers Squibb's EPS for 2024 stood at -$4.41, a 213.7% decrease from 2023.

BMY earnings chart

BMY EPS growth history

Earnings per share growth rates over time
EPS Growth YoY (Quarterly)
153.1%
EPS growth YoY
178.7%
EPS growth 3Y avg
5.3%
EPS growth 5Y avg
N/A

Bristol-Myers Squibb has recorded an increase in EPS of 153.1% over the last 12 months (YoY, quarterly). For the last three years, BMY recorded an average annual EPS growth rate of 5.3%. Across the last decade, BMY had an average annual EPS growth of 14%.

BMY Earnings Waterfall

Breakdown of revenue, profit and net income for Bristol-Myers Squibb

BMY Earnings vs Peers

What are the earnings of BMY compared to its peers
Stock name Price to Earnings EPS grwoth 1Y EPS grwoth 3Y EPS grwoth 5Y
BMY Bristol-Myers Squibb Company 14.65 178.7% 5.3% N/A
PFE Pfizer Inc 19.32 -3.5% -37.4% -3.7%
AZN Astrazeneca plc 23.24 45.4% 46% 22%
NVS Novartis AG 23.34 21.8% 31.2% 15.2%
AMGN AMGEN Inc 26.74 88.1% 5.6% 2.9%
JNJ Johnson & Johnson 29.14 90.6% 17.7% 14.8%
ABT Abbott Laboratories 35.18 -51.4% -1.8% 8.2%
MRK Merck & Co Inc 36.4 8% 8.4% 21.2%
LLY Lilly(Eli) & Company 40.5 95.6% 49.2% 27.5%
ABBV Abbvie Inc 123.78 -1.3% -29.1% -2.8%

All data is based on quarterly TTM periods, unless otherwise specified.